Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 7, Issue 7 (2018)

Current scenario of biosimilar

Author(s):
Pooja Paul, Harvinder Popoli, Ankit Saxena, Anamika Jaiswal and Sudha Sah
Abstract:
Biosimilar has gained popularity in past I past few years. A biosimilar is a formally regulated and approved duplicate of an originator biologic therapy. Globally, we are seeing that a growing number of biosimilar applications and approvals. The progress of a biosimilar is significantly more complex and expensive than a small molecule generic product. The medication of many diseases, particularly cancer, has been extremely impacted by the overview of biologic therapies (biologics), which are integrated into the treatment algorithms of most oncology clinical practice guidelines. Emerging market regulators should be authorised to make the risk-benefit decisions that are most suitable for the healthcare system in their country. In the last few years, India has seen a robust development in its biosimilar portfolio. The Indian biosimilar market is composed for big growth, augured by the launch of new products, growing acceptance of biosimilar. This review discusses the current state of knowledge on biosimilar.
Pages: 188-193  |  439 Views  10 Downloads
How to cite this article:
Pooja Paul, Harvinder Popoli, Ankit Saxena, Anamika Jaiswal, Sudha Sah. Current scenario of biosimilar. Pharma Innovation 2018;7(7):188-193.
The Pharma Innovation Journal